Physician profile
Charles B Yang
NPI 1992784250
$5,764.48
in general payments reported to CMS, 2019-2025
23 companies · $3,281 in 2025
The $3,281 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $351 · 2021: $155 · 2022: $185 · 2023: $718 · 2024: $799 · 2025: $3,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $2,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $2,298.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $2,690.15 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $926.25 | 2022-2025 | Lumigan, Xen Glaucoma Treatment System, Durysta |
| Allergan, INC. | $412.18 | 2019-2022 | |
| Rxsight INC | $343.64 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Alcon Vision LLC | $305.91 | 2019-2025 | Hydrus Microstent |
| New World Medical,INC. | $301.63 | 2021-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Tarsus Pharmaceuticals, INC. | $136.61 | 2024 | Xdemvy |
| Thea Pharma INC. | $110.64 | 2024-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $107.25 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $59.21 | 2019 | |
| Ocular Therapeutix, INC. | $55.84 | 2023-2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.74 | 2019 | |
| The Cameron-Ehlen Group, INC. | $39.63 | 2019 | |
| Apellis Pharmaceuticals, INC. | $33.75 | 2024-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $32.45 | 2023-2024 | Miebo, Xiidra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $25.90 | 2024 | Vevye |
| Glaukos Corporation | $25.18 | 2025 | Istent Infinite, Idosetr |
| Biotissue Holdings INC. | $24.72 | 2019-2020 | |
| Ivantis, INC | $22.46 | 2021 | |
| Rayner Intraocular Lenses Limited | $20.38 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Oyster Point Pharma, INC. | $14.45 | 2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.